Insight Molecular Diagnostics (IMDX) Operating Expenses (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Operating Expenses data on file, last reported at $4.4 million in Q1 2026.

• Quarterly Operating Expenses fell 45.49% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.7 million (down 17.91% YoY) and the FY2025 annual result came in at $53.4 million, down 13.53% from the prior year.
• Operating Expenses retreated to $4.4 million in Q1 2026 per IMDX's latest filing, from $23.9 million in the prior quarter.
• The five-year high for Operating Expenses was $34.2 million in Q4 2024, with the low at -$5.8 million in Q1 2023.
• Average Operating Expenses over 5 years is $9.6 million, with a median of $8.6 million recorded in 2023.
• The widest YoY moves for Operating Expenses: up 416.96% in 2023, down 278.92% in 2023.
• Insight Molecular Diagnostics' Operating Expenses stood at $11.6 million in 2022, then surged by 38.22% to $16.1 million in 2023, then soared by 113.06% to $34.2 million in 2024, then sank by 30.07% to $23.9 million in 2025, then plunged by 81.5% to $4.4 million in 2026.
• Business Quant data shows IMDX's Operating Expenses at $4.4 million in Q1 2026, $23.9 million in Q4 2025, and $11.2 million in Q3 2025.